Humankind vs. Cancer: The Scorecard
In this session, our panel of senior leaders from across the cancer research and development ecosystem discuss the new targeted therapies and breakthrough immuno-oncology drugs that are reaching patients at an accelerating pace, as well as the challenges and unanswered questions that still remain.
Jonathan Simons, President and CEO, Prostate Cancer Foundation; Senior Advisor, Milken Institute
Chris Boshoff, Senior Vice-President, Head Immuno-Oncology, Early Development and Translational Oncology, Pfizer
André Choulika, Chairman and CEO, Cellectics
Carlo Greco, Director of Clinical Research, Champalimaud Centre for the Unknown
Nils Lonberg, Senior Vice President, Oncology Discovery Biology, Bristol-Myers Squibb
Richard Paulson, Vice President and General Manager, Oncology, Amgen, Inc.
Suzanne Topalian, Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins